<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="215">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01242774</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589G2101</org_study_id>
    <secondary_id>EUDRACT 2009-016809-42</secondary_id>
    <nct_id>NCT01242774</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients &lt; 65 Years Old With Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to assess the maximum tolerated dose (MTD) of panobinostat
      given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with
      induction chemotherapy (idarubicin and cytarabine) in newly diagnosed patients with a
      cytopathologically confirmed diagnosis of high-risk AML, and to investigate the safety of
      the combination in this regimen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Define the maximum tolerated dose of Panobinostat (LBH589) that can be given with standard idarubicin and ara-C chemotherapy measured by safety and tolerability.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the number of patients who have safety and tolerability events</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine Panobinostat's pharmacokinetic parameters (study the amount of Panobinostat in a person's blood over time) following study treatments</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the response of  Panobinostat (LBH589) given with standard idarubicin and ara-C chemotherapy (as defined by Cheson 2003)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Panobinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <description>Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.</description>
    <arm_group_label>Panobinostat</arm_group_label>
    <other_name>LBH589</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed adult patients = 65 years old with a cytopathologically confirmed
             diagnosis of high-risk AML

          -  = 20% bone marrow blasts via bone marrow aspiration or biopsy

          -  The patient has not yet been treated for AML

          -  1ยบ or 2ยบ AML patients with high-risk category features

          -  ECOG PS = 2

          -  Renal function and liver function limits.

        Exclusion Criteria:

          -  Patient with a 'favorable' or 'better-risk' cytogenetic profile = t(15;17); t(8;21);
             or inv(16) or t(16;16)

          -  Patient has clinical symptoms suggestive of CNS leukemia and/or CSF findings for CNS
             leukemia

          -  Prior treatment with deacetylase inhibitors (DACi) including, panobinostat

          -  Impaired cardiac function

          -  Female patient who is pregnant or breast feeding

          -  Male patient who is not willing to use a barrier method of contraception

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+1 800 340 6843</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Medeiros, M.D.</last_name>
      <phone>650-736-4031</phone>
    </contact>
    <investigator>
      <last_name>Bruno Medeiros, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Faber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel DeAngela, M.D.</last_name>
      <phone>617-632-2645</phone>
    </contact>
    <investigator>
      <last_name>Daniel DeAngela, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State Comprehensive Cancer Center/James Cancer Hospitial/ClinicalTrials Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Walker, M.D.</last_name>
      <phone>614-293-2268</phone>
    </contact>
    <investigator>
      <last_name>Allison Walker, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina/Clinical Trials Office</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Stuart, M.D.</last_name>
      <phone>843-793-9756</phone>
    </contact>
    <investigator>
      <last_name>Robert Stuart, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center/Clinical Trials Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Strickland, M.D.</last_name>
      <phone>615-936-0831</phone>
    </contact>
    <investigator>
      <last_name>Stephen Strickland, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center/Clinical Trials Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Garcia-Manero, M.D.</last_name>
      <phone>713-794-1557</phone>
    </contact>
    <investigator>
      <last_name>Guillermo Garcia-Manero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 7, 2011</lastchanged_date>
  <firstreceived_date>October 17, 2010</firstreceived_date>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis  Pharmaceuticals</organization>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>bone marrow</keyword>
  <keyword>abnormal blast cells of myeloid</keyword>
  <keyword>acute leukemia</keyword>
  <keyword>cytogenetic abnormalities</keyword>
  <keyword>HDACi</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
</clinical_study>
